NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
Aarti Drugs Ltd. reported Q4 FY24 results that exceeded our expectations. revenue, Ebitda, and profit after tax grew by 2.3%, 22.3%, and 34.4% QoQ, respectively. Gross margins improved by 282 basis points sequentially due to a better product mix and a decline in input costs.
Additionally, Ebitda margins improved by 227 bps sequentially, driven by operating leverage from enhanced capacity utilisation. In the Formula Business segment, there was a notable growth of 19% YoY.
However, the specialty chemicals segment witnessed subdued numbers due to lower demand in the export segment.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
'Buy' LT Foods Shares Maintains Motilal Oswal To Get An Upside Of 28% — Here's Why
Aug 12, 2025
.png?rect=0%2C0%2C3500%2C1969&w=75)
Delhivery Q1 Results Review — PL Capital Downgrades To 'Add' Amid Sharp Appreciation In Stock Price
Aug 04, 2025
HUL Q1 Results Review: Systematix Maintains 'Hold', Hikes Target Price — Here's Why
Aug 01, 2025
Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'
Jul 28, 2025
POPULAR